Table 1 Demographic and clinical data of the new onset uveitis patients
From: New onset or recurrence of uveitis following COVID-19 infection
Patient number (age/sex/eye) | Time from COVID − 19 RT-PCR to uveitis (day) | Etiology | Clinical examination on admission | Treatment | Duration of follow up (day) | Outcome at last follow-up | ||
|---|---|---|---|---|---|---|---|---|
BCVA | IOP | BCVA | IOP | |||||
Patient 1 (47/F/OU) | 2 | Vogt-Koyanagi-Harada disease | CF; CF | 19.1, 18.5 | Topical Steroids Oral Steroids Ciclosporin | 65 | 0.3, 0.6 | 20.1, 19.2 |
Patient 2 (29/F/OU) | 1 | Vogt-Koyanagi-Harada disease | HM; CF | 9.9, 9.3 | Topical Steroids Oral Steroids Ciclosporin | 58 | 0.2, 0.3 | 11.3, 11.4 |
Patient 3 (27/M/OU) | 14 | Vogt-Koyanagi-Harada disease | CF; CF | 10.1, 12.5 | Topical Steroids Oral Steroids Ciclosporin | 60 | 0.1, 0.5 | 12.4, 12.2 |
Patient 4 (25/M/OU) | 2 | Sympathetic Ophthalmia | HM, 0.2 | 14.1, 12.4 | Oral Steroids | 53 | NLP, 0.3 | 10.3, 18.8 |
Patient 5 (38/F/OU) | 7 | Anterior Uveitis | 0.2, 0.4 | 13.6, 14.6 | Topical Steroids Peribulbar methylprednisolone injection | 34 | 0.3, 1.0 | 11.3, 14.5 |
Patient 6 (36/F/OD) | 20 | Anterior Uveitis | 0.8, 1.0 | 13.4, 15.6 | Topical Steroids Peribulbar methylprednisolone injection | 55 | 1.0, 1.0 | 12.4, 12.6 |
Patient 7 (58/M/OU) | 13 | Anterior Uveitis | 0.8, 0.8 | 18.9, 18.2 | Topical Steroids Peribulbar methylprednisolone injection | 92 | 0.8, 0.8 | 16.4, 17.1 |
Patient 8 (46/M/OU) | 7 | Anterior Uveitis (Posner-Schlossman Syndrome) | 0.6, 0.2 | 32.4, 30.8 | Topical Steroids IOP-lowering medication Trabeculectomy surgery | 90 | 0.8, 0.6 | 12.4, 16.4 |
Patient 9 (31/F/OS) | 7 | Choroiditis | 1.0, 0.4 | 13.2, 12.3 | Topical Steroids, Oral Steroids | 62 | 1.0, 1.0 | 14.4, 14.1 |